Immuneering (IMRX) Leases (2020 - 2024)
Immuneering (IMRX) has 5 years of Leases data on record, last reported at $3.7 million in Q3 2024.
- For Q3 2024, Leases fell 8.21% year-over-year to $3.7 million; the TTM value through Sep 2024 reached $3.7 million, down 8.21%, while the annual FY2023 figure was $4.0 million, 9.35% down from the prior year.
- Leases reached $3.7 million in Q3 2024 per IMRX's latest filing, down from $3.8 million in the prior quarter.
- Across five years, Leases topped out at $5.3 million in Q4 2021 and bottomed at $537181.0 in Q3 2021.
- Average Leases over 5 years is $3.6 million, with a median of $4.1 million recorded in 2023.
- Peak YoY movement for Leases: skyrocketed 768.4% in 2021, then decreased 17.21% in 2022.
- A 5-year view of Leases shows it stood at $613103.0 in 2020, then surged by 768.4% to $5.3 million in 2021, then fell by 17.21% to $4.4 million in 2022, then fell by 9.35% to $4.0 million in 2023, then fell by 6.19% to $3.7 million in 2024.
- Per Business Quant database, its latest 3 readings for Leases were $3.7 million in Q3 2024, $3.8 million in Q2 2024, and $3.9 million in Q1 2024.